Amicus brief of over 300 reproductive health researchers supports mifepristone's safety and effectiveness.

IF 3.4 2区医学 Q1 DEMOGRAPHY

Perspectives on Sexual and Reproductive Health Pub Date : 2024-07-29 DOI:10.1111/psrh.12282

Amanda Barrow, Cathren Cohen, Jaclyn Serpico, Melissa Goodman, Daniel Grossman, Sarah Raifman, Ushma Upadhyay

引用次数: 0

Abstract

On January 30, 2024, over 300 researchers filed an amicus brief in FDA v. Alliance for Hippocratic Medicine, a United States (US) Supreme Court case concerning the regulatory status of mifepristone, one of two drugs used in medication abortion. In this Comment we summarize the legal challenge, responses from the FDA and drug manufacturer to these challenges, oral arguments presented before the Court, and the implications of the Court's decision on access to mifepristone in the US. We also summarize the content of the accompanying amicus brief.

查看原文本刊更多论文

由 300 多名生殖健康研究人员组成的法庭之友支持米非司酮的安全性和有效性。

2024 年 1 月 30 日，300 多名研究人员在美国食品和药物管理局诉希波克拉底医学联盟一案中提交了一份法庭之友书状，该案涉及米非司酮的监管地位，米非司酮是用于药物流产的两种药物之一。在本评论中，我们概述了法律挑战、FDA 和药物制造商对这些挑战的回应、向法院提交的口头辩论，以及法院的裁决对在美国使用米非司酮的影响。我们还概述了随附的法庭之友书状的内容。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Perspectives on Sexual and Reproductive Health Multiple-

CiteScore

5.10

自引率

3.40%

发文量

期刊介绍： Perspectives on Sexual and Reproductive Health provides the latest peer-reviewed, policy-relevant research and analysis on sexual and reproductive health and rights in the United States and other developed countries. For more than four decades, Perspectives has offered unique insights into how reproductive health issues relate to one another; how they are affected by policies and programs; and their implications for individuals and societies. Published four times a year, Perspectives on Sexual and Reproductive Health includes original research, special reports and commentaries on the latest developments in the field of sexual and reproductive health, as well as staff-written summaries of recent findings in the field.